Trovagene Investor Relations Trovagene Investor Relations Trovagene Announces Leadership Change William Welch has resigned as CEO and Director Fri, 22 Jun 2018 14:19:00 -0700 Trovagene Announces the Start of Recruitment and Enrollment for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® in Patients with mCRPC Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute and Massachusetts General Hospital officially activated and recruiting patients for Phase 2 open-label trial of PCM-075 and abiraterone acetate (Zytiga®) in metastatic Castration-Resistant Prostate Cancer (mCRPC) Thu, 21 Jun 2018 05:00:00 -0700 Trovagene Announces Completion of First Dosing Cohort of Patients Treated with PCM-075 in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial Safety Review Committee (SRC) recommends proceeding to the second dosing cohort of PCM-075 in combination with decitabine in dose-escalation phase of trial Fri, 15 Jun 2018 05:00:00 -0700 Trovagene, Inc. Announces Closing of $18 Million Public Offering Tue, 12 Jun 2018 10:05:00 -0700 Trovagene, Inc. Announces Pricing of $18 Million Public Offering Thu, 07 Jun 2018 20:21:00 -0700